Cellogie Heart

Plant-Based Nutritional Support for the Heart

Cellogie HeartThe heart is probably one of the most important organs in your body, and functionally, it can never take a break!

Every cell in your body requires proper blood flow and it all starts with the pumping of your heart.

Cellogie-Heart uses some of nature’s best plants that have been shown to help with strengthening the heart and helping to increase cardiac output.

Scientific data also supports that the ingredients in Cellogie are able to lower elevated blood cholesterol levels.

With the plants’ abilities to lower inflammation in the blood vessels, Cellogie-Heart provides an excellent cardiovascular support that begins with the heart and ends with your cells.

Cellogie Heart Tablets

These tablets contain:

  • Hawthorn (Crataegus laevigata) – this reduces blood cholesterol levels, (BMC Complement Altern Med. 2012), helps to protect the heart and reduces the damages that can occur following heart injury. (Phytomedicine. 2010).
     
    ‘Current research to date suggests that hawthorn may potentially present a safe, effective, nontoxic agent in the treatment of cardiovascular disease and ischemic heart disease.’ (Pharmacogn Rev. 2010).
  • Hawthorn (Crataegus spp.) – Since the 1800s, natural health products that contain hawthorn (Crataegus spp.) have been used in North America for the treatment of heart problems such as hypertension, angina, arrhythmia and congestive heart failure. (Phytochemistry. 2012).
     
    Planta Med. 2011 ‘shows a review of 4000 patients have provided evidence for clinical benefits in the therapy of mild chronic heart failure.
     
    Besides cardiotonic effects, recent pharmacological investigations indicate that hawthorn extracts also possess cardio- and vasoprotective properties.
     
    Therefore, these extracts may also be employed in the prophylactic and therapeutic treatment of such conditions as endothelial dysfunction, atherosclerosis, coronary heart disease or prevention of restenosis/reocclusion following peripheral endovascular treatment.’

Hawthorn